WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58
npj Vaccines · 10.09.2024 · 9 (1)
DOI: 10.1038/s41541-024-00949-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift npj Vaccines, online erschienen am 10.09.2024. Verfasst von Troy J Kemp und 12 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine, Immunity, and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, CCR NIH HHS, Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation).
Abstract (Originalsprache)
Previously established World Health Organization (WHO) International Standards (IS) for anti-HPV16 and HPV18 antibodies are used to harmonize results across human papillomavirus (HPV) serology assays. Here, we present an international collaborative study to establish ISs for antibodies against HPV6 (NIBSC code 19/298), HPV11 (20/174), HPV31 (20/176), HPV33 (19/290), HPV45 (20/178), HPV52 (19/296) and HPV58 (19/300). The candidate standards were prepared using sera from naturally infected individuals. Each candidate was shown to be monospecific for reactivity against its indicated HPV type except for the HPV11 candidate, which was also reactive against other types. Expression of antibody levels relative to the relevant candidate IS reduced inter-laboratory variation allowing greater comparability between laboratories. Based on these results, the WHO Expert Committee on Biological Standardization established each of the 7 candidates as the 1st IS for antiserum to its indicated HPV type for use in the standardization of HPV pseudovirion-based neutralization and antibody-binding assays.
Autor:innen und Institutionen
- Vaccine, Immunity, and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
- Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Atlanta, GA, USA.
- Karolinska Institutet, Karolinska Universitetssjukhuset, Huddinge, Sweden.
- National Institutes for Food and Drug Control, Beijing, PR China.
- UK Health Security Agency, Virus Reference Department, London, UK.
- Medicines and Healthcare products Regulatory Agency (MHRA), South Mimms, UK.
Förderung
- NCI NIH HHS
- CCR NIH HHS
- Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation)
- U.S. Department of Health & Human Services | National Institutes of Health
Zitieren
APA
Kemp, T. J., Panicker, G., Eklund, C., Nie, J., Wang, Y., Beddows, S., Rigsby, P., Huang, W., Dillner, J., Unger, E. R., Pinto, L. A., Wilkinson, D. E., & collaborative study participants (2024). WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58. npj Vaccines, 9(1). https://doi.org/10.1038/s41541-024-00949-2
Vancouver
Kemp TJ, Panicker G, Eklund C, Nie J, Wang Y, Beddows S, et al. WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58. npj Vaccines. 2024;9(1). doi:10.1038/s41541-024-00949-2
BibTeX
@article{Kemp2024,
author = {Kemp, Troy J and Panicker, Gitika and Eklund, Carina and Nie, Jianhui and Wang, Youchun and Beddows, Simon and Rigsby, Peter and Huang, Weijin and Dillner, Joakim and Unger, Elizabeth R and Pinto, Ligia A and Wilkinson, Dianna E and collaborative study participants, collaborative study participants},
title = {WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58},
journal = {npj Vaccines},
year = {2024},
volume = {9},
number = {1},
doi = {10.1038/s41541-024-00949-2}
}
EUVIMED